News

Former Satori CEO & Pfizer Executive Jeffrey Ives Joins Board of Astrocyte Pharmaceuticals

Cambridge, Mass., December 1, 2014 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Ives, Ph.D. has joined the company’s Board of Directors. Dr. Ives brings extensive scientific expertise in neuroscience, medicinal chemistry, drug metabolism and pharmacokinetics as well as broad business expertise in biotech partnerships, R&D operations, clinical development, and financing.

Astrocyte Pharmaceuticals Inc. is a new drug development company dedicated to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.   The company is developing a proprietary small molecule pharmaceutical agent for acute administration to patients who have suffered a TBI, concussion or stroke.

Dr. Ives has over 30 years of senior scientific leadership experience in the development of novel therapeutics, with an emphasis on drugs for central nervous system diseases. Dr. Ives is a Principal for NeuroPharma Advisors, LLC, a Boston area advisory group dedicated to assisting companies developing therapeutics for central nervous system diseases. Prior to NeuroPharma Advisors, Dr. Ives was CEO of Satori Pharmaceuticals, which was a leading company in the development of gamma-secretase modulators for the treatment of Alzheimer’s disease. Before Satori, Dr. Ives held numerous senior management and scientific leadership positions at Pfizer including Senior Vice President of Pharmacokinetics, Dynamics and Metabolism, Vice President of Central Nervous System Research, and Executive Director of Central Nervous System Medicinal Chemistry.

“Jeff brings incredible knowledge and experience to Astrocyte at this formative time of our company. Jeff is deeply knowledgeable in multiple disciplines at the core of our science and business, and he will be instrumental in guiding the company’s advancement of our promising candidates,” stated Astrocyte CEO, William Korinek, Ph.D.

Dr. Ives earned his Ph.D. in Chemistry from Yale University and his Bachelor’s degree in Chemistry from Colgate University. In addition to the Astrocyte Board, Dr. Ives also serves on the Board of Directors for Cara Therapeutics and Acumen Pharmaceuticals.

For more information about Astrocyte Pharmaceuticals please contact Dr. Korinek at 617-444-8765 or info@astrocytepharma.com.

About Astrocyte Pharmaceutical Inc.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from TBI, concussion, stroke and neurodegenerative disorders such as Alzheimer’s disease. Founded in 2014 and based in Cambridge, Mass., the company works in partnership with the University of Texas Health Science Center at San Antonio (UTHSCSA).

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders